Antibody Testing Is Not Currently Recommended to Assess Immunity After COVID-19 Vaccination

The U.S. Food and Drug Administration (FDA) is reminding the public and health care providers that results from currently authorized SARS-CoV-2 antibody tests should not be used to evaluate a person’s level of immunity or protection from COVID-19 at any time, and especially after the person received a COVID-19 vaccination.

While a positive antibody test result can be used to help identify people who may have had a prior SARS-CoV-2 infection, more research is needed in people who have received a COVID-19 vaccination. Currently authorized SARS-CoV-2 antibody tests have not been evaluated to assess the level of protection provided by an immune response to COVID-19 vaccination. If antibody test results are interpreted incorrectly, there is a potential risk that people may take fewer precautions against SARS-CoV-2 exposure. Taking fewer steps to protect against SARS-CoV-2 can increase their risk of SARS-CoV-2 infection and may result in the increased spread of SARS-CoV-2.

The FDA is providing additional information and recommendations to the public and health care providers about the use of antibody tests in people who received a COVID-19 vaccination.

abfind post vaccination neutralizing antibody test
abfind post vaccination neutralizing antibody test

Recommendations for People Who Had or May Have a SARS-CoV-2 Antibody Test

  • Be aware that SARS-CoV-2 antibody tests help health care providers identify whether someone has antibodies to SARS-CoV-2, the virus that causes COVID-19, indicating a prior infection with the virus. However, more research is needed to understand the meaning of a positive or negative antibody test, beyond the presence or absence of antibodies, including in people who received a COVID-19 vaccination, in people who have been exposed and have SARS-CoV-2 antibodies, and in people who are not fully vaccinated.
  • If you have not been vaccinated: Be aware that a positive result from an antibody test does not mean you have a specific amount of immunity or protection from SARS-CoV-2 infection. If you have a positive test result on a SARS-CoV-2 antibody test, it means that it is possible you were previously infected with the SARS-CoV-2 virus. Talk with your health care provider about the meaning of your SARS-CoV-2 antibody test results.
  • If you received a COVID-19 vaccination: Continue to follow the CDC’s recommendations for fully vaccinated people. Be aware that if you have a positive test result on a SARS-CoV-2 antibody test, it is possible you were previously infected with SARS-CoV-2. A COVID-19 vaccination may also cause a positive antibody test result for some but not all antibody tests. You should not interpret the results of your SARS-CoV-2 antibody test as an indication of a specific level of immunity or protection from SARS-CoV-2 infection. Talk to your health care provider or your state and local health departments if you have questions about whether an antibody test is right for you.

Recommendations for Health Care Providers

  • At this time, do not interpret the results of qualitative, semi-quantitative, or quantitative SARS-CoV-2 antibody tests as an indication of a specific level of immunity or protection from SARS-CoV-2 infection after the person has received a COVID-19 vaccination. While a positive antibody test can indicate an immune response has occurred (seroconversion), and failure to detect such a response may suggest a lack of immune response, more research is needed. Currently authorized SARS-CoV-2 antibody tests are not validated to evaluate specific immunity or protection from SARS-CoV-2 infection. SARS-CoV-2 antibody tests should be ordered only by health care providers who are familiar with the use and limitations of the test. For more information about antibody tests for SARS-CoV-2, see Serology/Antibody Tests: FAQs on Testing for SARS-CoV-2.
  • Be aware that vaccines trigger antibodies to specific viral protein targets. For example, currently authorized COVID-19 mRNA vaccines induce antibodies to the spike protein and not to nucleocapsid proteins that are likely detected only after natural infections. Therefore, COVID-19 vaccinated people who have not had previous natural infection will receive a negative antibody test result if the antibody test does not detect the antibodies induced by the COVID-19 vaccine. If you are considering antibody testing in vaccinated individuals, follow the Centers for Disease Control and Prevention’s guidelines for antibody testing. For more information about antibody test performance visit EUA Authorized Serology Test Performance.

 

 

Anti-BTLA Neutralizing Antibody

100244 100 µg
EUR 355
Description: This anti-BTLA antibody is a purified recombinant human monoclonal antibody which recognizes the human BTLA protein. BTLA (B- and T-lymphocyte attenuator) belongs to the CD28 immunoglobulin superfamily (IgSF) and is an immune-regulatory receptor that binds to HVEM (Herpesvirus entry mediator, also known as TNFRSF14, Tumor necrosis factor receptor superfamily member 14). This antibody has been tested for specific binding to purified human BTLA protein and neutralizes the interaction between BTLA and HVEM.

Anti-VEGF Neutralizing Antibody

79478-1 50 µg
EUR 355
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

Anti-VEGF Neutralizing Antibody

79478-2 100 g
EUR 460
Description: Anti-VEGF recombinant Human antibody. This antibody not been tested for cross-reactivity with other species.

Anti-LAG3, Neutralizing Antibody

71219 100 µg
EUR 530
Description: Neutralizing recombinant human antibody recognizing the Lag-3 binding region.

Anti-VISTA Neutralizing Antibody

101293 100 µg
EUR 450
Description: This human monoclonal antibody recognizes human V-domain immunoglobulin (Ig) suppressor of T cell activation (VISTA), and neutralizes its interaction with VSIG3 (also called IGSF11). VISTA is also known as B7-H5 or VSIR (GenBank Accession No. NM_022153). VSIG3 is a ligand involved in cell adhesion as a VISTA binding partner. This neutralizing antibody has been functionally tested using the VSIG-3:VISTA [Biotinylated] Inhibitor Screening Assay Kit (BPS Bioscience #79782).

Anti-RANKL Neutralizing Antibody

100874-1 50 µg
EUR 335
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-RANKL Neutralizing Antibody

100874-2 100 µg
EUR 460
Description: Human, recombinant monoclonal antibody recognizing the RANKL protein, also known as TNFSF11 antibody and CD254 antibody. This antibody recognizes human RANKL. It has not been tested with other species. MW= 50 kDa (Heavy chain); 24 kDa (Light chain).

Anti-PCSK9 Neutralizing Antibody

71207 50 µg
EUR 555
Description: Neutralizing recombinant human antibody (IgG1) recognizing the LDLR binding region of human PCSK9.

Anti-TIGIT Neutralizing Antibody

71340 100 µg
EUR 565
Description: Human Anti-TIGIT neutralizing antibody recognizing the TIGIT binding region on immune cells.

Anti-PD-1 Neutralizing Antibody

71120 100 µg
EUR 465
Description: Neutralizing recombinant murine/human chimeric antibody recognizing the PD-L1/PD-L2 binding region of human PD-1. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Interferon alpha Neutralizing Antibody

20-abx137013
  • EUR 427.20
  • EUR 627.60
  • 0.5 mg
  • 1 mg

Anti-IL-17A Neutralizing Antibody

91015 100 µg
EUR 490
Description: Neutralizing recombinant human_x000D_chimeric antibody recognizing human IL-17A._x000D_This antibody has not been tested for crossreactivity_x000D_with other species.

Anti-β-Amyloid Neutralizing Antibody

71223 100 µg
EUR 465
Description: Purified, recombinant, humanized Anti-β-amyloid (IgG1) antibody, expressed in HEK293 cells. This antibody reacts with human β-amyloid and has not been tested for cross-reactivity with other species.

Anti-CTLA4 (CD152) Neutralizing Antibody

71212 100 µg
EUR 490
Description: Neutralizing recombinant human monoclonal antibody recognizing the extracellular domain of CTLA4 and blocking binding of CTLA4 to B7.1 and B7.2. This antibody recognizes human CTLA4 but does not bind to murine CTLA4. This antibody has not been tested for cross-reactivity with other species.

Anti-PD-L1 (CD274) Neutralizing Antibody

71213 100 µg
EUR 505
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested.

Monoclonal NGF/proNGF Neutralizing Antibody Antibody

AMM06679G 0.05mg
EUR 633.6
Description: A Monoclonal antibody against Human NGF/proNGF Neutralizing. The antibodies are raised in Mouse. This antibody is applicable in E

SARS-CoV-2 Neutralizing Antibody ELISA Kit

CSB-EL33243HU 96Т
EUR 595
Description: serum, plasma

Anti-COVID-19 S-IgM Neutralizing Antibody

E38A9973 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-IgA Neutralizing Antibody

E38A9974 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-hIgG1 Neutralizing Antibody

E38A9970 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-mIgG1 Neutralizing Antibody

E38A9971 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-COVID-19 S-cIgG1 Neutralizing Antibody

E38A9972 100ug/100ul
EUR 225
Description: Available in various conjugation types.

Anti-NGF (Nerve Growth Factor) Neutralizing Antibody

100436-1 50 µg
EUR 355
Description: Anti-NGF Neutralizing Recombinant Human antibody. This_x000D_ antibody has not been tested for crossreactivity_x000D_ with other species.

Anti-NGF (Nerve Growth Factor) Neutralizing Antibody

100436-2 100 µg
EUR 490
Description: Anti-NGF Neutralizing Recombinant Human antibody. This_x000D_ antibody has not been tested for crossreactivity_x000D_ with other species.

Anti-PD-1 Neutralizing Antibody, Biotin-labeled

71215 100 µg
EUR 510
Description: Purified, recombinant, human anti-PD-1 (IgG1) antibody with C-terminal Avitag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody does not cross-react with mouse PD-1, but does cross-react with monkey (M. fascicularis) PD-1. It has not been tested with other species.

Anti-2019-nCoV S-IgM Neutralizing Antibody (8A5)

EPT006 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-IgA Neutralizing Antibody (8A5)

EPT018 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-PD-L1 Neutralizing Antibody, Biotin-labeled

71214 100 µg
EUR 510
Description: Purified, recombinant, chimeric murine/human anti-PD-L1 (IgG1) antibody with C-terminal Avi-tag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody reacts with human PD-L1 and cross-reacts with mouse PD-L1. It has not been tested for cross-reactivity with other species.

Anti-2019-nCoV S-hIgG1 Neutralizing Antibody (8A5)

EPT031 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-mIgG1 Neutralizing Antibody (8A5)

EPT084 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Anti-2019-nCoV S-cIgG1 Neutralizing Antibody (8A5)

EPT085 50ug
EUR 239.4
Description: The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Mouse anti-COVID-19 S-mIgG1 Neutralizing Antibody

DL99726A-100ul 100 ul
EUR 299
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Mouse anti-COVID-19 S-mIgG1 Neutralizing Antibody

DL99726A-50ul 50 ul
EUR 210
Description: Spike glycoprotein; S glycoprotein; E2; Peplomer protein

Anti-PCSK9 Neutralizing Antibody, (IgG1) Biotin-labeled

71216 50 µg
EUR 530
Description: Purified recombinant human_x000D_anti-PCSK9 (IgG1) antibody with a C-terminal_x000D_Avi-tag, expressed in HEK293 cells. Purified_x000D_antibody was enzymatically biotinylated using_x000D_AviTag™ technology. This antibody reacts with_x000D_human PCSK9 and has not been tested for_x000D_cross-reactivity with other species.

Anti-PCSK9 Neutralizing Antibody, (IgG4) Biotin-labeled

71217 50 µg
EUR 515
Description: Purified recombinant human_x000D_anti-PCSK9 (IgG4) antibody with a C-terminal_x000D_Avi-tag, expressed in HEK293 cells. Purified_x000D_antibody was enzymatically biotinylated using_x000D_AviTag™ technology. This protein reacts with_x000D_human PCSK9 and has not been tested for_x000D_cross-reactivity with other species.

Leave a Comment